Hanson Group has introduced advanced international biomedical technologies and is committed to building a full-process clinical-grade CGT CDMO platform within China’s pharmaceutical industrial parks. Focusing on the field of cell therapy, the Group provides one-stop services covering process development, IND application, IIT clinical trials, pilot-scale production, and commercial manufacturing. Its services cover major cell therapy categories including CAR-T, ARST, NK, TIL, IEG, and iPS stem cells, strictly complying with NMPA GMP, GCP, and international standards such as FDA and EMA, filling the gap in high-end cell therapy CDMO capacity in Northeast China.

Production configuration: 20 independent B+A isolation production lines, each capable of handling different cell therapy projects simultaneously without interference. Annual capacity: 800–1,000 batches, covering preclinical process development, Phase I/II/III clinical production, and commercial pilot production. Service capacity: 40–60 IND applications and over 100 IIT clinical studies per year, meeting the needs of innovative pharmaceutical companies in Northeast China and across the country.